サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1793970

B型およびC型肝炎診断薬の世界市場

Hepatitis B and C Diagnostics

出版日
ページ情報
英文 275 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.30円
B型およびC型肝炎診断薬の世界市場
出版日: 2025年08月19日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 275 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

B型およびC型肝炎診断薬の世界市場は2030年までに96億米ドルに達する見込み

2024年に68億米ドルと推定されるB型およびC型肝炎診断薬の世界市場は、2024年から2030年にかけてCAGR 5.9%で成長し、2030年には96億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである免疫診断薬は、CAGR 4.9%を記録し、分析期間終了時には63億米ドルに達すると予測されます。核酸検査分野の成長率は、分析期間中CAGR 8.0%と推定されます。

米国市場は19億米ドルと推定、中国はCAGR 9.1％で成長予測

米国のB型およびC型肝炎診断薬市場は2024年に19億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに19億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.0％と5.7％と予測されています。欧州では、ドイツがCAGR 3.8%で成長すると予測されています。

世界のB型およびC型肝炎診断薬市場- 主要動向と促進要因まとめ

診断技術の革新は肝炎検出の展望を変えるか？

B型肝炎とC型肝炎の診断市場は、医療技術、分子生物学、ポイントオブケア検査の急速な進歩により、根本的な変革期を迎えています。これら2つのウイルス性肝炎は、合わせて世界中で数億人が罹患しているが、無症候性で進行すること、脆弱な集団におけるスクリーニングが限られていること、慢性症例におけるウイルスの挙動が複雑であることなどから、長らく診断上の課題となっていました。しかし、現在では新しい技術により、HBVとHCVの両方を、より早く、より正確に検出できるようになっています。分子アッセイ、特に核酸増幅検査（NAAT）は、活動性のウイルス感染を確認し、ウイルス量をモニタリングするためのゴールドスタンダードとして台頭してきています。これらの検査は感度と特異性が高く、低レベルのウイルスRNAやDNAも同定できるため、治療方針を決定する上で極めて重要です。同時に、酵素結合免疫吸着測定法（ELISA）や迅速診断試験（RDT）を含む血清学的検査の進歩により、特に低資源環境において、集団レベルでのスクリーニングがより現実的になりつつあります。乾燥血液スポット（DBS）検査、マルチプレックス・プラットフォーム、自動免疫測定システムなどの技術革新は、処理時間を短縮しながらスループットを向上させています。AIによる検査解釈やモバイル統合型診断リーダーを含むデジタル診断の台頭も、十分なサービスを受けていないコミュニティへのアクセスを拡大し、公衆衛生介入のためのデータ収集を改善しています。これらの技術革新が相まって、病院の検査室だけでなく、プライマリ・ケアや地域の診療所、遠隔地の保健センターへとB型およびC型肝炎診断薬を押し進め、早期介入や感染予防、疾病管理がこれまで以上に実現可能なものとなっています。

世界の肝炎撲滅の推進は、肝炎検診の普及につながるか？

世界保健機関（WHO）が主導する世界の公衆衛生イニシアチブは、肝炎診断をヘルスケアの最優先事項として高める上で重要な役割を果たしています。2030年までに公衆衛生の脅威としてのウイルス性肝炎を撲滅するというWHOの野心的な目標に伴い、各国は、特に薬物注射をする人々、囚人、セックスワーカー、HIV感染者などのハイリスク集団において、スクリーニング、診断、ケアへの連携を拡大するよう求められています。これを受けて、政府や非政府組織は、診断率を高めるために、地域ベースの検査プログラム、移動診療ユニット、対象を絞ったアウトリーチキャンペーンを強化しています。この努力の一環として、公衆衛生政策では、妊婦健診、献血、ヘルスケア従事者のスクリーニングにおいて、定期的な肝炎検査を義務付ける傾向が強まっており、検査の正常化と関連するスティグマの軽減に役立っています。さらに、世界基金、Gavi、UNITAIDなどの世界・ヘルス機関からの資金援助により、開発途上諸国は先進的な検査技術を調達し、検査能力を向上させ、肝炎診断薬を既存のヘルスケア・インフラに統合することが可能となっています。また、アジア太平洋、アフリカ、ラテンアメリカにおける地域的パートナーシップは、検査戦略の効率性と公平性を確保するために、知識の共有とガイドラインの標準化を促進しています。反射テストやワンステップ確認プロトコールなど、簡略化された診断アルゴリズムの採用は、スクリーニングから治療開始までの道のりをさらに加速しています。教育キャンペーンや啓発活動は、特に肝炎の理解が進んでいない地域社会で、検査を受けるよう促す上で重要な役割を果たしています。このような世界の協調運動は診断薬市場を再形成し、検査が世界の肝炎撲滅戦略の礎石となるにつれて、販売量と技術革新の両方を牽引しています。

分散型検査とポイントオブケアソリューションは、診断薬へのアクセスをどのように拡大しているか？

分散型検査やPOC（ポイント・オブ・ケア）診断ツールの利用が可能になりつつあることで、特に検査施設のインフラが最小限または存在しない、資源の限られた農村部でのB型およびC型肝炎検査へのアクセスが劇的に拡大しています。これらのコンパクトで使いやすい診断キットは、家庭、学校、コミュニティセンター、難民キャンプなど、従来の医療環境以外でも第一線の医療従事者が検査を実施できるようにすることで、アウトリーチに革命をもたらしています。ラテラルフロー免疫測定技術に基づくPOC検査では、HBV表面抗原（HBsAg）またはHCV抗体を迅速に検出することができ、わずか15～30分で結果が得られます。これらの検査の多くは、指を刺すだけの採血を必要とし、冷蔵に依存しないため、熱帯地域や十分なサービスを受けていない地域での展開に理想的です。さらに、マイクロ流体工学、バイオセンサー、バッテリー駆動の分析装置の進歩により、これらの分散型ツールの精度と信頼性が向上し、POC検査と集中型検査室での検査との性能差が縮まっています。POC検査をデジタル・ヘルス・プラットフォームと統合することで、結果の即時記録と送信が可能になり、リアルタイムの疾病サーベイランスとフォローアップ・ケアが容易になります。人道的環境や遠隔地のコミュニティでは、訓練を受けた非医師医療従事者がスクリーニングを実施するタスク・シフティング・モデルが、検査のカバー率と効率をさらに高めています。また、世界の調達イニシアティブにより、高負担国のための低価格診断薬が確保され、これらのソリューションの価格も改善されつつあります。このようなアクセスの民主化は、早期診断と早期介入を実現し、発見から治療までの時間を短縮し、より広範な肝炎撲滅目標を支援する上で特に不可欠です。分散型検査技術が進化し続けるにつれ、肝炎治療における物流、財政、地理的障壁を克服する上で、その役割はますます重要になるでしょう。

B型およびC型肝炎診断薬分野の成長を促進する主な市場勢力とは？

B型およびC型肝炎診断薬市場の成長は、疾患蔓延率の上昇、技術革新、ヘルスケア政策の進化、消費者行動や医療提供者の優先事項のパターンの変化に根ざしたいくつかの要因によってもたらされます。世界の肝炎罹患者数は3億5,000万人を超え、慢性HBVまたはHCVに罹患している患者数は膨大であるため、特に治療適格性が正確なウイルス定量にますます依存するようになっていることから、診断需要の重要な基盤となっています。人口の高齢化、注射薬使用率の上昇、有病率の高い国からの移住の増加は、リスクのある人口層をさらに拡大しています。技術面では、次世代分子プラットフォーム、デジタルイムノアッセイ、AIを活用した診断分析の登場が、検査の精度、スピード、手頃な価格を加速させています。一方、医薬品の進歩、特にC型肝炎の治療薬である直接作用型抗ウイルス薬（DAAs）の登場は、より多くの患者を診断に向かわせ、治療と診断の間に需要のフィードバックループを生み出しています。欧州、北米、アジアの規制機関は、血液銀行、出産前ケア、入院におけるスクリーニングの義務化を実施し、公衆衛生政策における肝炎検査の役割を制度化しています。同時に、パンデミック時代のキャパシティ・ビルディングに支えられた診断インフラへの世界の投資は、肝炎検査の拡大に再利用されつつあります。消費者の行動も変化しています。ヘルスリテラシーの向上、自己検査の常態化、デジタルヘルスツールによって、個人が積極的に検査を受けるようになりつつあります。民間の診断検査機関、遠隔医療サービス、在宅検査キットは、カスタマイズされたサービスで対応し、アクセスをさらに多様化しています。これらの力が相まって、医療上の必要性だけでなく、イノベーションとアクセスにも関わる急速に進化する市場が形成されつつあり、肝炎診断薬は世界の感染症との闘いにおける重要なフロンティアとして位置づけられています。

セグメント

タイプ（免疫診断薬、核酸検査）;疾患タイプ（B型肝炎、C型肝炎）

調査対象企業の例

  • Abbott Laboratories
  • Affymetrix（Thermo Fisher）
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • Biomerieux SA
  • Cepheid（Danaher）
  • DiaSorin S.p.A.
  • Fujirebio（H.U. Group）
  • Grifols, S.A.
  • Hologic, Inc.
  • HORIBA, Ltd.
  • InTec Products, Inc.
  • Johnson & Johnson
  • MedMira Inc.
  • Ortho Clinical Diagnostics
  • Qiagen N.V.
  • Roche Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Trinity Biotech

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37076

Global Hepatitis B and C Diagnostics Market to Reach US$9.6 Billion by 2030

The global market for Hepatitis B and C Diagnostics estimated at US$6.8 Billion in the year 2024, is expected to reach US$9.6 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Immunodiagnostics, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$6.3 Billion by the end of the analysis period. Growth in the Nucleic Acid Testing segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 9.1% CAGR

The Hepatitis B and C Diagnostics market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Hepatitis B and C Diagnostics Market - Key Trends & Drivers Summarized

Are Innovations in Diagnostic Technology Changing the Outlook for Hepatitis Detection?

The diagnostics landscape for Hepatitis B and C is undergoing a fundamental transformation driven by rapid advancements in medical technology, molecular biology, and point-of-care testing. These two forms of viral hepatitis, which collectively affect hundreds of millions worldwide, have long posed diagnostic challenges due to asymptomatic progression, limited screening in vulnerable populations, and the complexity of viral behavior in chronic cases. However, new technologies are now enabling earlier, faster, and more accurate detection of both HBV and HCV. Molecular assays, particularly nucleic acid amplification tests (NAATs), are emerging as the gold standard for confirming active viral infection and monitoring viral load. These tests offer high sensitivity and specificity, capable of identifying even low levels of viral RNA or DNA, which is critical for guiding treatment decisions. Simultaneously, advances in serological testing, including enzyme-linked immunosorbent assays (ELISA) and rapid diagnostic tests (RDTs), are making population-level screening more feasible, especially in low-resource settings. Innovations such as dried blood spot (DBS) testing, multiplex platforms, and automated immunoassay systems are increasing throughput while reducing turnaround times. The rise of digital diagnostics, including AI-assisted test interpretation and mobile-integrated diagnostic readers, is also extending access to underserved communities and improving data collection for public health interventions. Collectively, these innovations are pushing Hepatitis B and C diagnostics beyond hospital laboratories and into primary care, community clinics, and remote health centers-making early intervention, prevention of transmission, and disease management more achievable than ever before.

Is the Global Push for Elimination Driving Widespread Hepatitis Screening Initiatives?

Global public health initiatives, particularly those spearheaded by the World Health Organization (WHO), are playing a crucial role in elevating hepatitis diagnostics as a top healthcare priority. With WHO’s ambitious goal to eliminate viral hepatitis as a public health threat by 2030, countries are being urged to scale up screening, diagnosis, and linkage to care-especially among high-risk populations such as people who inject drugs, prisoners, sex workers, and individuals living with HIV. In response, governments and non-governmental organizations are ramping up community-based testing programs, mobile health units, and targeted outreach campaigns designed to increase diagnosis rates. As part of this effort, public health policies are increasingly mandating routine hepatitis testing in antenatal care, blood donations, and healthcare worker screenings, helping to normalize testing and reduce associated stigma. Additionally, funding from global health organizations such as the Global Fund, Gavi, and UNITAID is enabling developing countries to procure advanced testing technologies, improve laboratory capacity, and integrate hepatitis diagnostics into existing healthcare infrastructure. Regional partnerships in Asia-Pacific, Africa, and Latin America are also fostering knowledge sharing and standardized guidelines to ensure that testing strategies are both efficient and equitable. The adoption of simplified diagnostic algorithms-such as reflex testing and one-step confirmatory protocols-is further accelerating the path from screening to treatment initiation. Educational campaigns and awareness drives are playing a crucial role in encouraging individuals to get tested, particularly in communities where hepatitis remains poorly understood. This coordinated global movement is reshaping the diagnostics market, driving both volume and innovation as testing becomes a cornerstone of hepatitis elimination strategies worldwide.

How Are Decentralized Testing and Point-of-Care Solutions Expanding Access to Diagnostics?

The growing availability of decentralized and point-of-care (POC) diagnostic tools is dramatically expanding access to Hepatitis B and C testing, particularly in resource-limited and rural areas where laboratory infrastructure is minimal or nonexistent. These compact, easy-to-use diagnostic kits are revolutionizing outreach by enabling frontline health workers to conduct testing outside of traditional medical settings, such as in homes, schools, community centers, and refugee camps. POC tests based on lateral flow immunoassay technology allow for rapid detection of HBV surface antigen (HBsAg) or HCV antibodies with results in as little as 15 to 30 minutes. Many of these tests require only a finger-prick blood sample and do not rely on refrigeration, making them ideal for deployment in tropical or underserved regions. Moreover, advances in microfluidics, biosensors, and battery-powered analyzers are improving the accuracy and reliability of these decentralized tools, narrowing the performance gap between POC tests and centralized laboratory assays. Integration of POC testing with digital health platforms enables immediate recording and transmission of results, which facilitates real-time disease surveillance and follow-up care. In humanitarian settings and remote communities, task-shifting models-where trained non-physician health workers conduct screenings-are further increasing testing coverage and efficiency. The affordability of these solutions is also improving, with global procurement initiatives ensuring reduced-cost diagnostics for high-burden countries. This democratization of access is especially vital in achieving early diagnosis and intervention, reducing the time from detection to treatment, and supporting broader hepatitis elimination targets. As decentralized testing technologies continue to evolve, their role in overcoming logistical, financial, and geographic barriers to hepatitis care will only become more central.

What Key Market Forces Are Fueling Growth in the Hepatitis B and C Diagnostics Sector?

The growth in the Hepatitis B and C diagnostics market is driven by several factors rooted in rising disease prevalence, technological innovation, healthcare policy evolution, and shifting patterns in consumer behavior and provider priorities. The sheer scale of the global hepatitis burden-over 350 million individuals living with chronic HBV or HCV-provides a significant base for diagnostic demand, especially as treatment eligibility increasingly depends on precise viral quantification. Aging populations, rising rates of injection drug use, and increased migration from high-prevalence countries are further expanding the at-risk demographic. On the technological front, the emergence of next-generation molecular platforms, digital immunoassays, and AI-powered diagnostic analytics is accelerating test accuracy, speed, and affordability. Meanwhile, pharmaceutical advancements-particularly the availability of curative direct-acting antivirals (DAAs) for hepatitis C-are motivating more patients to seek diagnosis, creating a feedback loop of demand between treatment and diagnostics. Regulatory bodies across Europe, North America, and Asia are implementing screening mandates in blood banks, prenatal care, and hospital admissions, institutionalizing the role of hepatitis testing in public health policy. Concurrently, global investments in diagnostic infrastructure-bolstered by pandemic-era capacity building-are being repurposed to expand hepatitis testing. Consumer behavior is also changing; increased health literacy, the normalization of self-testing, and digital health tools are empowering individuals to proactively seek testing. Private diagnostic laboratories, telehealth services, and at-home testing kits are responding with customized services, further diversifying access. Combined, these forces are shaping a rapidly evolving market that is as much about innovation and access as it is about medical necessity-positioning hepatitis diagnostics as a critical frontier in the global fight against infectious diseases.

SCOPE OF STUDY:

The report analyzes the Hepatitis B and C Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Immunodiagnostics, Nucleic Acid Testing); Disease Type (Hepatitis B, Hepatitis C)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • Affymetrix (Thermo Fisher)
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • Biomerieux SA
  • Cepheid (Danaher)
  • DiaSorin S.p.A.
  • Fujirebio (H.U. Group)
  • Grifols, S.A.
  • Hologic, Inc.
  • HORIBA, Ltd.
  • InTec Products, Inc.
  • Johnson & Johnson
  • MedMira Inc.
  • Ortho Clinical Diagnostics
  • Qiagen N.V.
  • Roche Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Trinity Biotech

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Hepatitis B and C Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Chronic Hepatitis Infections Throws the Spotlight on Early and Accurate Diagnostics
    • Increased Government-Led Screening Initiatives Propel Growth in Population-Wide Testing Programs
    • Global Commitment to Viral Hepatitis Elimination Expands Addressable Market for Diagnostic Solutions
    • Advancements in Rapid Point-of-Care Testing Drive Adoption in Resource-Limited Settings
    • Integration of Molecular Diagnostics Strengthens Business Case for High-Sensitivity Viral Load Testing
    • Growing Public Health Focus on Blood Safety Generates Demand for Routine Hepatitis Screening
    • Widespread Use of Combination Panels and Multiplex Testing Spurs Efficiency in Diagnostic Workflows
    • Technological Innovation in PCR and Next-Generation Sequencing Accelerates Diagnostic Accuracy
    • Increased Access to Affordable Diagnostics Through Global Health Partnerships Sustains Market Growth
    • Expansion of At-Home and Self-Testing Solutions Drives Consumer-Centric Hepatitis Testing
    • Healthcare Digitization and Data Integration Throw the Spotlight on Real-Time Epidemiological Tracking
    • Rising Co-Infection Risks with HIV and TB Generate Demand for Integrated Diagnostic Platforms
    • Lack of Awareness and Underdiagnosis in Low-Income Regions Pose Persistent Challenges to Market Penetration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hepatitis B and C Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hepatitis B and C Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunodiagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immunodiagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Immunodiagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Nucleic Acid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Nucleic Acid Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Nucleic Acid Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hepatitis B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hepatitis B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hepatitis B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hepatitis C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hepatitis C by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hepatitis C by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • JAPAN
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • CHINA
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • EUROPE
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Hepatitis B and C Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • FRANCE
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • GERMANY
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • INDIA
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Hepatitis B and C Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Hepatitis B and C Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030
  • AFRICA
    • Hepatitis B and C Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Hepatitis B and C Diagnostics by Type - Immunodiagnostics and Nucleic Acid Testing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Hepatitis B and C Diagnostics by Type - Percentage Breakdown of Value Sales for Immunodiagnostics and Nucleic Acid Testing for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Hepatitis B and C Diagnostics by Disease Type - Hepatitis B and Hepatitis C Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Hepatitis B and C Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Hepatitis B and Hepatitis C for the Years 2014, 2025 & 2030

IV. COMPETITION